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The embryological basis 
of subclinical hypertrophic 
cardiomyopathy
Gabriella Captur1, Carolyn Y. Ho2, Saskia Schlossarek3,4, Janet Kerwin5, Mariana Mirabel6, 
Robert Wilson7, Stefania Rosmini8, Chinwe Obianyo8, Patricia Reant9, Paul Bassett10, 
Andrew C. Cook8, Susan Lindsay5, William J. McKenna8, Kevin Mills1, Perry M. Elliott8,11, 
Timothy J. Mohun7, Lucie Carrier3,4 & James C. Moon8,11
Hypertrophic cardiomyopathy (HCM) is caused by mutations in sarcomeric proteins, the commonest 
being MYBPC3 encoding myosin-binding protein C. It is characterised by left ventricular hypertrophy 
but there is an important pre-hypertrophic phenotype with features including crypts, abnormal mitral 
leaflets and trabeculae. We investigated these during mouse cardiac development using high-resolution 
episcopic microscopy. In embryonic hearts from wildtype, homozygous (HO) and heterozygous (HET) 
Mybpc3-targeted knock-out (KO) mice we show that crypts (one or two) are a normal part of wildtype 
development but they almost all resolve by birth. By contrast, HO and HET embryos had increased 
crypt presence, abnormal mitral valve formation and alterations in the compaction process. In scarce 
normal human embryos, crypts were sometimes present. This study shows that features of the human 
pre-hypertrophic HCM phenotype occur in the mouse. In an animal model we demonstrate that there 
is an embryological HCM phenotype. Crypts are a normal part of cardiac development but, along with 
the mitral valve and trabeculae, their developmental trajectory is altered by the presence of HCM 
truncating Mybpc3 gene mutation.
Hypertrophic cardiomyopathy (HCM) is the commonest monogenic heart disease (estimated prevalence 1 in 500), 
predominantly caused by autosomal dominant mutations in sarcomere protein genes1,2. Over 350 individual 
MYPBC3 mutations have been identified, representing 40–50% of all HCM mutations, making it the most 
frequently mutated gene in this disease (Fig. 1). The majority of MYPBC3 mutations are predicted to encode 
truncated proteins that lack portions of the C-terminus.
The majority of HCM patients survive into young adulthood3 but there are subgroups with a higher risk of 
sudden cardiac death and heart failure4. HCM is defined by unexplained left ventricular hypertrophy (LVH). 
Except for some neonatal forms of HCM5–7 where infants carry bi-allelic mutations, LVH typically appears for the 
first time in adolescence or early adult life8. Ahead of this however, patients may express a distinct subclinical phe-
notype consisting of measurable architectural abnormalities. This includes the presence of multiple myocardial 
crypts9,10, abnormal trabecular patterning11 and anterior mitral valve leaflet (AMVL) elongation12. In addition, 
microvascular remodelling6 and markers of myocardial fibrosis13 and altered function14 (particularly hypercon-
tractility) may occur. As family screening of first-degree relatives is recommended in HCM15,16, the detection of 
this phenotype may be helpful in cases where genotyping is not definitive. Specific disease-modifying therapies 
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are being developed for HCM including subclinical disease17,18 so tracking the subclinical phenotype earlier in 
the disease may help treatment19. We have previously shown how the subclinical phenotype can predict HCM 
sarcomere gene mutation carriage20, but its etiology remains unknown.
There are some clues. The architectural features and its identification in small children6 suggests an origin dur-
ing cardiogenesis pre-birth. The noncompaction11,21 implies incomplete embryological compaction22 and poten-
tially the persistence of an embryonic cardiac state. How other subclinical HCM features (like crypts and AMVL 
elongation) arise, is unknown but suspected to be similar23.
We explored whether myocardial crypts were a normal feature of cardiac morphogenesis and disordered in 
HCM, looking also at trabeculae and the mitral valve. We studied the phenotypic impact of a Mybpc3 sarcom-
ere gene mutation on murine cardiac development using high-resolution episcopic microscopy24 (HREM). We 
imaged wildtype human neonatal and embryonic hearts to explore normal development and we used HREM to 
systematically examine the cardiac morphogenesis of wildtype and HCM mouse hearts. HREM visualizes the 
hearts in three-dimensions (3D) at high resolution. We used a Mybpc3-targeted KO (knock-out [KO]) mouse 
model of HCM25 Briefly, the model was based upon the targeted deletion of exons 1 and 2 from the endogenous 
Mybpc3 sarcomere gene, containing the transcription initiation site. In the homozygous (HO) state, KO mice 
develop LVH, systolic dysfunction and histopathological features of HCM shortly after birth while heterozygous 
(HET) KO exhibit later asymmetric septal hypertrophy25 (ASH) more akin to usual human HCM26,27.
Methods
All methods described were carried out in accordance with the approved relevant guidelines.
Normal embryonic, fetal and neonatal human hearts. We obtained this scarce resource from librar-
ies, and imaged them using micro-computerised tomography (CT), micro-magnetic resonance imaging (MRI), 
HREM or optical projection tomography28 (OPT) according to heart size (Supplementary Table 1), searching for 
crypts. We obtained two embryonic (CS20 and CS21) and one fetal (9 pcw) human heart (visually fixed in dias-
tole), from the Joint MRC/Wellcome-Trust (grant # 099175/Z/12/Z) Human Developmental Biology Resource29 
(HBDR, http://www.hdbr.org), with appropriate maternal written informed consent and approval from the 
Newcastle and North Tyneside NHS Health Authority Joint Ethics Committee. One fetal (19 pcw) and one neo-
natal human heart was obtained from University College London Institute of Child Health. Both are regulated 
by the UK Human Tissue Authority (HTA; www.hta.gov.uk) and operate in accordance with the relevant HTA 
Codes of Practice.
Figure 1. Schematic illustrating the mechanism of cMyBP-C haploinsufficiency in HET KO mice. 
(a) The cardiac sarcomere consists of thick-filament (myosin) and thin-filament proteins (actin, alpha cardiac 
muscle 1 [ACTC1], tropomyosin 1 alpha chain [TPM1], troponins I/C/T [TNNI3, TNNC1, TNNT2]) and titin. 
cMyBP-C is a sarcomeric protein located in the C zone of the A band that functions to stabilize sarcomere 
structure and regulate crossbridge cycling kinetics by controlling actomyosin interactions. Structurally wildtype 
cMyBP-C protein (b,e) consists of 12 domains of which 8 are immunoglobulin-like domains (pale green), 
and three are fibronectin domains (blue)55. Unique to cMyBP-C is a cardiac-specific C0 domain, a proline/
alanine-rich (P/A) linker sequence between C0 and C1 and a regulatory motif between domains C1 and C2 that 
contains phosphorylation sites (PPP). The cMyBP-C interactome is illustrated in (b) and annotated in (g). All 
heterozygous (HET) HO mice (left panel) had a wildtype and a mutant recombinant allele (c) resulting from 
the targeted ablation of the transcription initiation site and exons 1–2. The final effect of the mutation in KO is 
that of a true protein haploinsufficiency predicted to produce a lower level of full length protein. LMM = light 
meromyosin; MYH7 = β -myosin heavy chain cardiac muscle isoform; MYL2 = myosin regulatory light chain 2 
ventricular/cardiac muscle isoform; MYL3 = myosin light chain polypeptide 3; Neo = neomycin resistance gene; 
WT = wildtype.
www.nature.com/scientificreports/
3Scientific RepoRts | 6:27714 | DOI: 10.1038/srep27714
Animals. All mice (Mus musculus) were handled in accordance with the Guide for the Care and Use of 
Laboratory Animals published by the US National Institutes of Health and with the approval of the MRC National 
Institute of Medical Research Ethical Review Panel. Procedures were in accordance with the German Law for the 
Protection of Animals and accepted by the Ministry of Science and Public Health of the City State of Hamburg, 
Germany (Nr. ORG 696). Both KO and wildtype mice (Supplementary Table 2) were maintained on a C57Bl/6J 
background at the University Medical Center Hamburg-Eppendorf. The other larger population of wildtype 
mouse embryos was obtained from NIMR:Parkes (a robust outbred strain) and the inbred strain C57BL/6J main-
tained at the MRC National Institute of Medical Research. For approximate embryo staging, detection of a vaginal 
plug was taken as gestation day 0.5 (E0.5).
Embryo hearts were isolated as previously described30. These were dehydrated, infiltrated with methacrylate 
resin and used for HREM analysis24. Each HREM image stack comprised up to1300 short axis images, produce 
by successive removal of 2 μ m (E14.5-E16.5) or 3 μ m (E18.5-P0) sections. Mice were staged according to gesta-
tional age (Embryonic days) such that E0-0.9 refers to the one-cell embryo stage, E14.5 (Carnegie stage 22 in the 
human) marks the time when ventricular septation is complete and a dense trabecular meshwork is established 
within the ventricular cavities, E18.5 is immediately before birth and P0, the neonatal mouse.
Image processing and analysis of murine data. After optimization of grayscale mapping, HREM 
datasets were subscaled to 250 Mb for 3D volume-rendered reconstructions in OsiriX (an open source software 
package that permits interactive 3D visualisation; 64bit version) and scored by a single reader, blinded to murine 
group and stage, for the presence or absence of crypts on short-axis HREM stacks and cross-checked on 3D 
volumetric models of the lumens. The segmental location of crypts was noted relative to the American Heart 
Association 17-segment model. Linear caliper measurements of crypt depth and adjacent wall thickness were 
acquired (Table 1). Crypts ≥ 30% of adjacent wall thickness were considered for all subsequent analysis. Fractal 
analysis for trabecular complexity and relevant reproducibility and reslicing experiments have been previously 
described22. For LV wall thickness linear caliper measurements we extracted using a semi-automated radial 
spokes approach developed in-house (40° sectors superimposed upon the HREM short axis slices in a clockwise 
direction; implemented in Image J version 1.38× , National Institute of Health, Bethesda, MD, USA). All mitral 
valve measurements were made on the 3-chamber long-axis view (replicating the cardiac MRI method12). AMVL 
and PMVL length was measured using the open-poly region of interest tool while basal leaflet thickness was 
measured using linear calipers in OsiriX. Intra-observer variability was estimated for AMVL length and basal 
leaflet thickness (n = 35) in randomly-selected mouse embryo datasets by HREM. Intra- and inter-observer varia-
bility was estimated for myocardial crypt rulings (n = 40) in randomly-selected mouse embryo datasets by HREM 
using two readers blinded to each other’s rulings (GC and CO).
Statistical analysis. Statistical analysis was performed in R programming language (version 3.0.1, The R 
Foundation for Statistical Computing) and illustrations reporting bullseye plots constructed in MATLAB® (The 
MathWorks Inc., Natick, MA, USA, R2012b). Descriptive data are expressed as mean ± standard deviation (s.d.) 
except where otherwise stated. Distribution of data was assessed on histograms and using Shapiro-Wilk test. 
Categorical variables were compared by Fisher’s exact tests. Normally distributed continuous variables pertaining 
to wildtype, HO and HET KO were compared using analysis of variance (ANOVA) with Tukey’s post-hoc test. 
Intra- and inter-observer variability for crypt rulings was evaluated by the Cohen’s Kappa statistic. Intraclass 
correlation coefficient was used to compare variability of repeated mitral leaflet measurements. A two-factor 
fully cross-factored ANOVA model was used to compare FD between mutant and wildtype mouse populations. 
Covariate models (FD = X|A + ε, where epsilon signifies full replication) were constructed for the analysis of 
response FD to terms: X|A, where A was the fixed factor (WT, Het or HO KO mouse group), and covariate X the 
(numeric) relative slice position along the ventricle. A two-sided P value < 0.05 was considered significant.
Results
Singular crypts can be seen in the normal developing human heart. We show crypts could occur 
in the human embryo, observing one embryonic crypt at Carnegie Stage (CS) 21 and one fetal myocardial crypt 
at post-coital week (pcw) 9 (Figs 2 and 3a). No developing human heart exhibited multiple (≥ 2) crypts, an other-
wise relatively common finding in adult patients with the MYBPC3 mutation.
Myocardial crypts are normal in the developing murine heart but few persist till birth. In wildtype 
murine embryo hearts (n = 108, Fig. 4a) across two strains (C57BL/6J, n = 31; NIMR:Parkes, n = 77) crypts are 
normal and ubiquitous in the embryo (total of 58 crypts counted in 108 hearts), making their first appearance in 
wildtype shortly after ventricular septation (embryonic day 15.5 [E]). These resembled adult human crypts (see 
Supplementary Figure 4). Prevalence increased beyond E15.5 and peaked at E18.5 (72% of NIMR:Parkes and 70% 
of C57BL/6J hearts exhibited at least 1 crypt at E18.5). By birth (P0), and with progressive myocardial thickening, 
crypts involuted so their prevalence dropped to 11% in wildtype. Intra- and inter-observer variability for crypt 
rulings was high (Cohen’s Kappa: intra-observer, 0.93; inter-observer, 0.84).
Crypts are more abundant in the embryonic murine HCM heart. In HO KO, HET KO and wildtype 
littermates (n = 56 all on a C57BL/6J background, at both E18.5 and P0; HO KO n = 28, HET KO n = 16, wildtype 
n = 12) crypts are present in all at E18.5 but they persist to birth only in HO and HET KO mice, unlike wildtype 
(Figs 3c,d and 4b–g). When present, they are also more frequent (in total we counted 10 crypts in the wildtypes, 
46 crypts in the HET KO and 98 crypts in the HO KO, Table 1). See Supplementary Videos 1 and 2.
Abnormal development of the trabeculated myocardium in the embryo HCM heart. 
Trabeculation was quantified by fractal analysis22 (a higher value indicating more complexity31) in wildtype, HET 
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and HO KO mice (n = 56 at E18.5 and P0; wildtype, n = 12; HET n = 16, HO n = 28, all on a C57BL/6J back-
ground). At E18.5 the LV of HET KO is less compacted than wildtype (Fig. 5a), normalising by P0. By contrast 
however the apex of HO KO was more compacted (smoother) than wildtype at all stages (Fig. 5a,b). The RV was 
similar - Supplementary Figure 1.
HET KO mouse embryos do not show mitral valve leaflet elongation. We measured AMVL and 
posterior MVL (PMVL) length and basal leaflet thickness (Fig. 5c) in HCM and wildtype hearts at E18.5 and P0 
in a total of 56 mice at E18.5 and P0 (wildtype, n = 12; HET KO n = 16, HO KO n = 28, all on a C57BL/6J back-
ground). There was no difference in AMVL length or thickness between HET KO and wildtype (Fig. 5d) even 
after adjusting for LV cavity size. We measured a shorter AMVL in HO KO mice at E18.5 than in both wildtype 
and HET KO that persisted after adjusting for LV cavity size at E18.5 (for HO KO compared to wildtype; P < 0.01, 
one-way ANOVA with Tukey correction). The AMVL of HO KO was also thinner than of wildtype at E18.5 and 
Wildtype HET KO HO KO
E18.5 P0 E18.5 P0 E18.5 P0
No. of mice 8 4 7 9 18 10
LV length (mm) 2.33 ± 0.11 2.54 ± 0.06 2.25 ± 0.15 2.38 ± 0.12 2.18 ± 0.12‡ 2.11 ± 0.06*,§
LV mid AP lumen (mm) 0.96 ± 0.10 1.01 ± 0.15 1.02 ± 0.04 0.91 ± 0.08 0.93 ± 0.07 0.86 ± 0.11‡
LV max. septal WT∞ (mm)
 Level-1 0.495 ± 0.059 0.598 ± 0.133 0.507 ± 0.077 0.568 ± 0.040 0.528 ± 0.044 0.566 ± 0.053
 Level-2 0.481 ± 0.022 0.603 ± 0.102 0.527 ± 0.079 0.661 ± 0.039 0.570 ± 0.046‡ 0.580 ± 0.068~
 Level-3 0.566 ± 0.033 0.645 ± 0.051 0.577 ± 0.061 0.659 ± 0.067 0.573 ± 0.042 0.582 ± 0.075~
 Level-4 0.520 ± 0.065 0.648 ± 0.135 0.527 ± 0.077 0.602 ± 0.039 0.587 ± 0.049 0.565 ± 0.066
 Level-5 0.458 ± 0.026 0.585 ± 0.071 0.444 ± 0.061 0.577 ± 0.044 0.540 ± 0.064‖ 0.532 ± 0.072
LV max. lateral WT≠ (mm)
 Level-1 0.339 ± 0.059 0.443 ± 0.099 0.401 ± 0.55 0.416 ± 0.054 0.415 ± 0.068 0.465 ± 0.068
 Level-2 0.369 ± 0.033 0.470 ± 0.123 0.344 ± 0.039 0.434 ± 0.036 0.440 ± 0.074 0.423 ± 0.063
 Level-3 0.378 ± 0.025 0.493 ± 0.079 0.351 ± 0.035 0.431 ± 0.036 0.402 ± 0.040 0.429 ± 0.062
 Level-4 0.379 ± 0.021 0.525 ± 0.037 0.350 ± 0.051 0.419 ± 0.036 0.424 ± 0.040 0.440 ± 0.063
 Level-5 0.428 ± 0.038 0.563 ± 0.104 0.387 ± 0.062 0.470 ± 0.041 0.435 ± 0.038 0.459 ± 0.064
No. of mice with:
 0 crypts 3 1 – – – –
 1 crypt 3 3 2 – – –
 2 crypts 2 – 2 2 3 1
 3 crypts – – 2 4 5 2
 4 crypts – – – 3 5 –
 5 crypts – – – – 2 3
 6 crypts – – 1 – 1 2
 7 crypts – – – – 2 1
 8 crypts – – – – – 1
No. of mice with ≥ 1 crypt (%) 5 (63) 3 (75) 7 (100) 9 (100) 18 (100)‡ 10 (100)
No. of mice with ≥ 2 crypts (%) 2 (25) 0 (0) 5 (71) 9 (100)† 18 (100)* 10 (100)*
Crypt depth (mm) 0.187 ± 0.17 0.236 ± 0.16 0.184 ± 0.11 0.249 ± 0.02 0.224 ± 0.30 0.244 ± 0.02
Crypt depth:WT ratio (% ± se) 38.2 ± 4.1 49.0 ± 8.5 55.6 ± 1.8 55.4 ± 0.8 49.7 ± 0.5 52.7 ± 0.5
AMVL (mm)
 Length 0.472 ± 0.064 0.480 ± 0.072 0.451 ± 0.065 0.458 ± 0.060 0.365 ± 0.032*,‖ 0.399 ± 0.028
 Basal thickness 0.099 ± 0.024 0.094 ± 0.023 0.081 ± 0.018 0.062 ± 0.023 0.071 ± 0.024‡ 0.047 ± 0.009†
PMVL (mm)
 Length 0.249 ± 0.031 0.333 ± 0.078 0.247 ± 0.053 0.326 ± 0.056 0.238 ± 0.019 0.273 ± 0.031
 Basal thickness 0.065 ± 0.012 0.052 ± 0.013 0.046 ± 0.013 0.053 ± 0.014 0.060 ± 0.011 0.041 ± 0.013
Table 1. HREM summary data from wildtype, HET KO and HO KO mice. The segment-by-segment LV wall 
thickness data reproduced in Fig. 6 is organised in this table to permit comparisons of septal versus lateral wall 
thicknesses at the various levels. AMVL = anterior mitral valve leaflet; AP = anteroposterior; HREM = high-
resolution episcopic microscopy; No./nos = number/s; PMVL = posterior mitral valve leaflet; se = standard 
error. All values are expressed as mean ± standard deviation (s.d.) unless otherwise stated. ∞ Segments 1, 6, 7, 8 
and 9 are considered in the septal group. ≠ Segments 2, 3, 4 and 5 are considered in the lateral group. * Significantly 
different from wildtype same stage, p < 0.001. †Significantly different from wildtype same stage, p < 0.01. 
‡Significantly different from wildtype same stage, p < 0.05. §Significantly different from HET KO same stage, 
p < 0.001. ‖ Significantly different from HET KO same stage, p < 0.01. ~Significantly different from HET KO 
same stage, p < 0.05.
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P0 but not after adjusting for LV cavity size (P = 0.99 and P = 0.16 respectively). There were no differences in 
absolute and cavity-size-adjusted PMVL measurements between wildtype, HET and HO KO. Intraclass correla-
tion coefficients for repeated AMVL length and basal thickness measurements were high: 0.93, 95% confidence 
interval (CI) 0.90–0.96 and 0.91, 95% CI 0.87–0.95 respectively.
Subtle ASH is normal during development but exaggerated in the HCM mice. We measured 
embryonic LV wall thickness using a 45-myocardial segments model (Supplementary Figure 2). A total of 56 mice 
at E18.5 and P0 were included (wildtype, n = 12; HET KO n = 16, HO KO n = 28, all on a C57BL/6J background, 
Fig. 6). In the wildtype mouse at E18.5 and P0, the septum is 36% thicker than the lateral wall at base and mid 
levels (levels 1–3: P = 0.0004, P = 0.002, P < 0.0001 by one-way ANOVA with Tukey correction) but not at the 
apex (levels 4,5: P = 0.397, P = 0.43). This basal-to-mid ASH pattern is more pronounced in HET and HO KO (all 
P < 0.0001, pooled stages). The HO KO mice had smaller overall LV cavity size compared to wildtype at birth and 
thinner absolute (un-indexed to LV size) LV myocardial segmental thicknesses (Fig. 6 and Table 1). LV chamber 
size (Supplementary Figure 3) in HO KO was smaller than in wildtype and HET KO: LV base-to-apical length 
was reduced in HO KO at E18.5 compared to wildtype (P = 0.02) and at P0 compared to both wildtype and HET 
KO (P < 0.0001 both); LV lumen diameter (antero-posterior) was reduced in HO KO compared to wildtype at P0 
(P = 0.04). Data for the RV is provided in Supplementary Note 1.
Discussion
Before the development of LVH there exists in humans a detectable subclinical HCM phenotype consisting of 
crypts (particularly multiple), elongation of the anterior mitral valve leaflet, increased LV apical trabecular com-
plexity and smaller LV systolic volume, with the first two being the strongest predictors for sarcomere gene muta-
tion carriage20.
It has long been argued that at least some aspects of this subclinical phenotype may have a developmental 
origin8 but proof of this was lacking. Here we report that in an animal model of HCM, there is a measurable 
embryological HCM phenotype.
Mutant HO and HET KO mice that lacked or expressed reduced levels of MyBP-C protein in the heart, are not 
structurally normal in utero as was previously thought32 but they have more crypts, abnormal patterns of trabec-
ulation and the LVs of HO KO are smaller in size. While cardiac development is still able to proceed in spite of 
reduced or absent cMyBP-C levels, the cMyBP-C protein is essential for normal cardiac development.
Single myocardial crypts do occur in the general adult human population but multiple myocardial crypts are 
unusual in the healthy heart33,34. In the mouse, a reasonable and established model of human cardiac morpho-
genesis35, crypts are a normal and dynamic feature of the developing heart after ventricular septation supporting 
the literature descriptions by several authors of crypts being ‘congenital’36–38. In wildtype, crypts are most prev-
alent at E18.5 and typically disappear by birth, but crypts in HET and HO KO mutants are often multiple and 
persistent to birth. The location (predilection for RV superior and inferior insertion points) faithfully reflects 
adult human HCM crypts (see Supplementary Figure 4)39. We spotted only infrequent, singular crypts in the 
developing normal human heart, and although the number of hearts studied was small the data is in line with 
the murine findings. Since human myocardial crypts and late gadolinium enhancement by cardiac MRI due to 
plexiform fibrosis40 appear to share a similar predilection for RV superior and inferior insertion points41, further 
work should seek to explore the biomechanical or developmental factors potentially linking the two.
Figure 2. Crypts in developing human hearts. (a) A basal inferolateral crypt can be seen in this 3-chamber 
view of a CS21 human heart by OPT (asterix); (b) a mid anteroseptal crypt is seen in this short-axis view of a 
9 pcw human fetus by MRI (asterix). CS = Carnegie stage; MRI = magnetic resonance imaging; OPT = optical 
projection tomography; pcw = post-coital week.
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The mechanical environment during cardiogenesis directs stem cell differentiation42,43. At the time of myocar-
dial migration and differentiation of pluripotent epicardium-derived cells (EPDCs)44, the heart tube has already 
begun to contract and is actively expressing Mybpc344,45. It is reasonable to imagine that in mutants, the abnormal 
contractile properties of embryonic cardiomyocytes alter the tensile forces that converge on the RV insertion 
points, where muscle fibres are pulled apart creating deep crypts that the final myocardial compaction process 
after E18.5 cannot obliterate completely. Such crypts may therefore persist into the adult HCM heart.
AMVL elongation occurs in patients with overt and subclinical LVH12 and in adult HO Mybpc3 KO mice 
with overt LVH46, but the mechanism remains elusive. Two hypotheses exist: the ‘congenital’ hypothesis proposes 
that AMVL elongation has its origin in the developing heart influenced by the sarcomere gene mutation; and the 
‘acquired’ hypothesis, that the AMVL elongates postnatally in response to mechanical stretch from abnormal 
Figure 3. Myocardial crypts are congenital in humans and more abundant in embryonic HCM hearts. 
17-Segment American Heart Association bullseye plots indicate the relative number of crypts per left 
ventricular segment as a percentage of the total number of hearts per group. (a) Normal human embryo hearts 
were studied at CS20 by HREM and CS21 by OPT, latter corresponding to E14.5 in the mouse. Fetal hearts were 
studied at 9 pcw by MRI and at 19 pcw by micro-CT. The neonatal human heart was studied by MRI. Compared 
to wildtype (b), HET and HO KO mouse mutants (c,d) showed a higher prevalence of multiple (≥ 2) crypts 
(by Fisher’s exact test): HET KO vs. wildtype at P0, p = 0.001; HO KO vs. wildtype at E18.5 and P0, p < 0.001 
both. CT = computerized tomography; E = embryonic day; HREM = high-resolution episcopic microscopy; 
P0 = post-natal day 0. Other abbreviations as in Figs 1 and 2.
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loading conditions. The fact that the AMVL is not elongated in our HET KO mice supports the latter hypothesis 
and fits with our previous work11 where we demonstrated AMVL elongation in all patients with overt HCM 
regardless of the presence of a sarcomere gene mutation by next generation sequencing. In addition these elon-
gated leaflets in HCM patients have previously been shown to be histologically normal with no evidence of myx-
oid degeneration47.
It has been previously reported that HO KO mice on a Black Swiss background are born with an apparently 
normal cardiac phenotype32 only to develop increased heart-to-body-weight ratio by 2 weeks32 and reduced frac-
tional shortening (heart failure) by 3–4 months25. Here, high-resolution imaging and more sophisticated analysis 
tools using mice on a C57BL/6J background show that at E18.5, HO KO exhibit significant basal septal hypertro-
phy compared to wildtype and by P0 they develop thinner LV walls and the LVs are smaller. Similar mice with 
homozygous Mybpc3 gene mutations created by other researchers have been shown to develop dilated cardiomy-
opathy coupled with myocyte hyperplasia post-natally due to an extra round of postnatal cell division48.
Recent murine work has shown that doxycycline-induced inhibition of transgene expression of a different 
HCM-causing sarcomere gene mutation (α -myosin heavy chain gene49) only achieved LVH prevention when 
administered in utero, suggesting that the processes promoting LVH must be imprinted early in embryonic life. 
We show here embryonic patterning from HCM from the time of septation with altered cardiac developmental 
trajectory. It is for future studies to explore (potentially using imaging biomarkers similar to ours, as their surro-
gate end-points), whether primary preventative or therapeutic strategies for HCM are most effective when started 
sufficiently early: in utero for conditional transgenesis49; at birth for gene therapy50.
It has been hypothesized25 that the reduced cMyBP-C protein levels in KO might impair a molecular pathway 
through a deficit of interaction with a septum-specific protein, not yet identified, resulting in the development 
of age-dependent ASH in HET KO mice. Our data shows subtle ASH is the norm in wildtype mice at both E18.5 
and P0. A theory could be that the basal septum is embryologically programmed towards ASH but normally kept 
in check by a healthy array of sarcomere gene products. Sarcomere gene mutations could be disinhibiting this 
embryological program, resulting in the florid ASH patterns characteristic of adult HCM.
Humans with HCM-causing heterozygous sarcomere gene mutations have previously been shown to have 
abnormally increased trabecular complexity11 resembling the situation seen in the HET KO mice at E18.5 com-
pared to wildtype. Whilst this difference was not measurable at P0 (perhaps on account of the dramatic changes 
in LV wall structure and loading conditions at this stage), it is possible that the basis for abnormal trabecular for-
mation is imprinted in utero and becomes manifest later. The hypotrabeculation measured in HO KO (for which 
no adult human corollary exists) is consistent with the generalised cardiac underdevelopment observed (thinner 
walls, smaller cavities, shorter mitral leaflets).
Limitations. First, we did not perform deep phenotyping of KO mice earlier than E18.5 as our more extensive 
phenotyping exercise in wildtype C57BL/6J and NIMR:Parkes (n = 108) suggested that crypt differences would 
Figure 4. Myocardial crypts in the developing wildtype and HCM heart. (a) Crypt prevalence during 
development in wildtype mouse. Prevalence is calculated as a percentage of total number of hearts studied. 
Crypts are uncommon at E14.5 and E15.5, their prevalence increases between E16.5 and E18.5 but it falls again 
by P0 (when only 1 out of 9 NIMR:Parkes hearts exhibits a crypt). For C57BL/6J (BL6) and NIMR:Parkes 
(Parkes) strains respectively: E14.5, n = 13 and 15; E15.5, n = 0 and 14; E16.5, n = 8 and 13; E17.5, n = 0 and 
12; E18.5, n = 10 and 14; P0, n = 0 and 9. (b–g) Heart sections by HREM from HO KO, HET KO and wildtype 
littermates at E18.5 (b,d,f) and P0 (c,e,g) showing respectively the whole-heart 3D reconstruction as well as the 
digitally eroded coronal and mid-ventricular short-axis view. Examples of deep myocardial crypts (red arrows 
in d–g) are highlighted in the slices from HET and HO KO (also Supplementary Videos 1 and 2). Crypts are 
deep myocardial defects that point into the myocardial wall typically around the RV insertion points. Scale bars, 
all 0.5 mm. The same magnification has been applied to all short-axis images – HO KO at P0 is visibly smaller 
than both wildtype and HET KO. WT denotes wildtype. Abbreviations as in Figs 1 and 3.
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be most significant at E18.5 and beyond. Second, it was necessary to use non-HREM imaging methods to study 
available human embryonic/fetal/neonatal hearts for crypts and while organ preparation and fixation protocols 
will have differed, we only examined hearts that had been fixed after diastolic arrest permitting the crypt survey. 
We added potassium chloride during heart preparation for HREM to encourage such diastolic arrest, but as this 
may have been incomplete and because the imaging plane for crypt survey in mice (HREM short-axis stack) 
differed from that published for adult humans by dynamic cardiac MRI (long axis cines where precise diastolic 
gating was possible), we set our HREM cut-off for defining a crypt at ≥ 30% instead of ≥ 50%. Third, some other 
histological aspects of the extended HCM phenotype8 like myocardial disarray, interstitial fibrosis and coronary 
arteriolar changes have not been investigated in this work. Fourth, although we attempted to measure abnormal-
ities involving papillary muscles and chordae47 we found that accurate quantitative descriptions of these were 
not reliable in embryo hearts because of the density of myocardial trabeculae so no such data is presented. Fifth, 
we did not evaluate gender differences. Future work should be directed at elucidating the mechanism by which 
cMyBP-C protein haploinsufficiency in this model is altering the cardiac developmental trajectory, at studying 
mouse models with other types of Mybpc3 and non-Mybpc3 mutations, and to understand the impact of mouse 
genetic background on the severity of HCM phenotype expression.
In conclusion, adult human myocardial crypts first described in 195823, have a congenital origin. By expressing 
exaggerated crypt formation8 patients with subclinical HCM may be recapitulating an embryonic cardiac 
state51,52, one that usually ceases to exist in the mouse after E18.5. Our animal data provides the first quantitative 
Figure 5. Trabecular and mitral differences between wildtype, HET and HO KO mice. Trabecular 
complexity (a,b) is increased in HET KO and reduced in HO KO. Solid lines: group means. Ribbons: upper/
lower 95% confidence limits. FD11, an index of endocardial complexity (higher = more complex), was measured 
for each HREM slice. At E18.5 LV trabeculation in the basal half was higher in HET KO (FD mean ± s.d. in 
basal half: 1.540 ± 0.034) than in both wildtype (1.447 ± 0.055) and HO KO (1.462 ± 0.047, p < 0.0001 both, 
by ANOVA). At E18.5 and P0, the LV apex of HO KO (FD mean ± s.d. in the apical half at E18.5 and P0 
respectively: 1.560 ± 0.028 and 1.535 ± 0.034) was less noncompacted compared to wildtype (1.565 ± 0.024 and 
1.577 ± 0.012, p = 0.0003 and p < 0.0001 by ANOVA) and HET KO (1.590 ± 0.015 and 1.542 ± 0.016, p < 0.0001 
and p < 0.05 by ANOVA). At E18.5 and P0 respectively for wildtype n = 8 and n = 4; HET KO n = 7 and n = 9; 
HO KO n = 18 and n = 10. (c) MV measurements (red: freehand length; yellow: linear caliper thickness) were 
performed on zoomed 3-chamber views from 3D curved multiplanar HREM reconstructions. (d) AMVL 
is shorter in HO KO than in wildtype and HET KO at E18.5 (p < 0.001, p < 0.01 respectively by one-way 
ANOVA) and shorter than HET KO at P0 (p < 0.05). AMVL basal thickness was reduced in HO KO compared 
to wildtype at E18.5 and P0 (p < 0.05 and p < 0.01 respectively). There were no differences in PMVL length/
thickness between populations (Supplementary Table S6). Scale bar, 0.2 mm. Error bars, + sem. At E18.5 and P0 
respectively for wildtype n = 8 and n = 4; HET KO n = 7 and n = 9; HO KO n = 18 and n = 10. A/PMVL = anterior/
posterior mitral valve leaflet; FD = fractal dimension; LV = left ventricle; Other abbreviations as in Figs 1 and 3.
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evidence that cMyBP-C has the ability to alter the cardiac developmental trajectory53,54. These novel developmen-
tal insights should stimulate further research in this area with the potential to improve our understanding of the 
pathogenesis and molecular mechanisms of HCM.
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